Postoperative Outcome of Patients Who Underwent Total Joint Replacement During the Tanezumab Phase 3 Osteoarthritis Development Program: a 24-week Observational Study

Postoperative Outcome of Patients Who Underwent Total Joint Replacement During the Tanezumab Phase 3 Osteoarthritis Development Program: a 24-week Observational Study

Read the publication >

Contact Us

Phone Icon

T: +44 7413 022053

Email Icon

E: contact@ia-grp.com

Address Icon

8thFloor, 1 Butterwick, Hammersmith, London, W6 8DL United Kingdom

or

Pennovation, 3401 Grays Ferry Ave, Philadelphia, PA 19146, USA